Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III
Portal vein thrombosis is a major complication associated with liver cirrhosis. In cirrhotic patients, a decrease in procoagulant and anticoagulant factors and an unstable balance between them is observed, and a relative decrease in the activation of anticoagulant drivers is one of the main causes o...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Case Reports in Medicine |
Online Access: | http://dx.doi.org/10.1155/2020/8268016 |
id |
doaj-a0417fb7b7f642b6b64efd4f57372b0d |
---|---|
record_format |
Article |
spelling |
doaj-a0417fb7b7f642b6b64efd4f57372b0d2020-11-25T03:27:59ZengHindawi LimitedCase Reports in Medicine1687-96271687-96352020-01-01202010.1155/2020/82680168268016Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin IIISatoshi Nakayama0Naoya Murashima1Department of Gastroenterology, Mishuku Hospital, 5-33-12, Kamimeguro, Meguro-ku, Tokyo 153-0051, JapanDepartment of Gastroenterology, Mishuku Hospital, 5-33-12, Kamimeguro, Meguro-ku, Tokyo 153-0051, JapanPortal vein thrombosis is a major complication associated with liver cirrhosis. In cirrhotic patients, a decrease in procoagulant and anticoagulant factors and an unstable balance between them is observed, and a relative decrease in the activation of anticoagulant drivers is one of the main causes of portal vein thrombosis (PVT). Herein, we report a case of acute portal thrombosis associated with liver cirrhosis and treated with a recombinant form of soluble thrombomodulin (thrombomodulin alpha, TM-α) in combination with antithrombin III. TM-α was administered in accordance with the dosage and route of administration for disseminated intravascular coagulation therapy and resulted in dissolution of PVT with a gradual decrease in D-dimer levels. No adverse events were observed during the course of treatment. In the future, in addition to conventional anticoagulation therapy using heparin or antivitamin K drugs, novel therapies targeting protein C activation using a recombinant form of soluble thrombomodulin may play an important role in the treatment of acute PVT.http://dx.doi.org/10.1155/2020/8268016 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Satoshi Nakayama Naoya Murashima |
spellingShingle |
Satoshi Nakayama Naoya Murashima Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III Case Reports in Medicine |
author_facet |
Satoshi Nakayama Naoya Murashima |
author_sort |
Satoshi Nakayama |
title |
Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III |
title_short |
Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III |
title_full |
Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III |
title_fullStr |
Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III |
title_full_unstemmed |
Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III |
title_sort |
acute portal vein thrombosis treated with recombinant human soluble thrombomodulin combined with antithrombin iii |
publisher |
Hindawi Limited |
series |
Case Reports in Medicine |
issn |
1687-9627 1687-9635 |
publishDate |
2020-01-01 |
description |
Portal vein thrombosis is a major complication associated with liver cirrhosis. In cirrhotic patients, a decrease in procoagulant and anticoagulant factors and an unstable balance between them is observed, and a relative decrease in the activation of anticoagulant drivers is one of the main causes of portal vein thrombosis (PVT). Herein, we report a case of acute portal thrombosis associated with liver cirrhosis and treated with a recombinant form of soluble thrombomodulin (thrombomodulin alpha, TM-α) in combination with antithrombin III. TM-α was administered in accordance with the dosage and route of administration for disseminated intravascular coagulation therapy and resulted in dissolution of PVT with a gradual decrease in D-dimer levels. No adverse events were observed during the course of treatment. In the future, in addition to conventional anticoagulation therapy using heparin or antivitamin K drugs, novel therapies targeting protein C activation using a recombinant form of soluble thrombomodulin may play an important role in the treatment of acute PVT. |
url |
http://dx.doi.org/10.1155/2020/8268016 |
work_keys_str_mv |
AT satoshinakayama acuteportalveinthrombosistreatedwithrecombinanthumansolublethrombomodulincombinedwithantithrombiniii AT naoyamurashima acuteportalveinthrombosistreatedwithrecombinanthumansolublethrombomodulincombinedwithantithrombiniii |
_version_ |
1715207125306703872 |